109 Therapeutics, Inc. — National Science Foundation SBIR Phase I: BM
109 Therapeutics, Inc. — SBIR Phase I award from National Science Foundation.
- Amount
- $255,838
- Agency
- National Science Foundation
- Program / Phase
- SBIR · Phase I
- Topic
- BM
- NAICS
- —
- Place of performance
- UT
- Period
- 2020-09-01 → 2021-08-31
Description
The broader impact /commercial potential of this Small Business Innovation Research (SBIR) Phase I project develops novel pain therapeutics that can reduce or eliminate the use of opioids after surgery. Opioid-based medications are a mainstay of postopera